Article Information
History
- December 14, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Paul K. Drain1,2,*,
- Madhavi Ampajwala3,
- Christopher Chappel4,
- Andre B. Gvozden5,
- Melanie Hoppers6,
- Melody Wang1,
- Robert Rosen7,
- Stephen Young8,
- Edward Zissman9 and
- Michalina Montano1
- 1Department of Global Health, University of Washington, Seattle, WA, USA
- 2Department of Medicine, University of Washington, Seattle, WA, USA
- 3Village Health Partners, Plano, TX, USA
- 4Chappel Group, Kissimmee, FL, USA
- 5Gvozden Pediatrics, Millersville, MD, USA
- 6Clinical Research Solutions, Jackson, TN, USA
- 7Ardmore Family Practice, Winston-Salem, NC, USA
- 8Tricore Reference Laboratories, Albuquerque, NM, USA
- 9Children’s Research, LLC, Altamonte Springs, FL, USA
- ↵*Corresponding Author:
Paul K. Drain, MD, MPH, 325 Ninth Ave, UW Box 359927; Seattle, WA 98104-2420, Email:
pkdrain{at}uw.edu; Fax:
206-520-3831; Phone: 206-520-3820
Posted December 14, 2020.
A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care
